8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 7, 2026·SEC
Editas Medicine, Inc.(EDIT)Earnings, Financials & Key Ratios
EDIT•NASDAQ
Price updated Jun 19, 2026
AboutEditas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Show more
- Revenue$41M+25.4%
- EBITDA-$94M+61.7%
- Net Income-$160M+32.5%
- EPS (Diluted)-1.80+37.5%
- Gross Margin100%
- EBITDA Margin-232.13%+69.4%
- Operating Margin-245.15%+68.5%
- Net Margin-395.01%+46.2%
- ROE-198.14%-102.0%
EDIT Key Insights
Editas Medicine, Inc. (EDIT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗High debt to equity ratio of 2.8x
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Sales declining 14.9% over 5 years
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EDIT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EDIT Price & Volume
Editas Medicine, Inc. (EDIT) stock price & volume — 10-year historical chart
Loading chart...
EDIT Growth Metrics
Editas Medicine, Inc. (EDIT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years37.9%
5 Years-14.89%
3 Years27.15%
TTM7.97%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM56.63%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM59.61%
Return on Capital
10 Years-43%
5 Years-46.85%
3 Years-52.95%
Last Year-49.1%
EDIT Recent Earnings
Editas Medicine, Inc. (EDIT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 6/12 qtrs (50%)
Q2 2026Latest
May 5, 2026Metric
Actual
Est
EPS
$0.26+13.3%
$0.30
Rev
$3M-55.6%
$6M
Q2 2026
Mar 9, 2026Metric
Actual
Est
EPS
$0.06+77.8%
$0.27
Rev
$25M+196.3%
$8M
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.28+26.3%
$0.38
Rev
$8M-10.8%
$8M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.63-53.7%
$0.41
Rev
$4M+97.0%
$2M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 5, 2026 | $0.26vs $0.30+13.3% | $3Mvs $6M-55.6% |
| Q2 2026 | Mar 9, 2026 | $0.06vs $0.27+77.8% | $25Mvs $8M+196.3% |
| Q4 2025 | Nov 10, 2025 | $0.28vs $0.38+26.3% | $8Mvs $8M-10.8% |
| Q3 2025 | Aug 12, 2025 | $0.63vs $0.41-53.7% | $4Mvs $2M+97.0% |
Based on last 12 quarters of dataView full earnings history →
EDIT Peer Comparison
Editas Medicine, Inc. (EDIT) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CRSP | 5.22B | 54.09 | -8.36 | -89.97% | -138.57% | -30.88% | 0.21 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 SGMO | 74.57M | 0.18 | -0.41 | -31.57% | -356.89% | -28.92% | ||
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 ACMR | 7.28B | 109.87 | 80.20 | 15.24% | 9.48% | 5.13% | 0.16 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare EDIT vs Peers
Editas Medicine, Inc. (EDIT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EDIT Income Statement
Editas Medicine, Inc. (EDIT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 13.73M | 31.94M | 20.53M | 90.73M | 25.54M | 19.71M | 78.12M | 32.31M | 40.52M | 38.69M |
Revenue Growth % | 126.8% | 132.64% | -35.71% | 341.93% | -71.85% | -22.83% | 296.32% | -58.64% | 25.39% | 7.97% |
Cost of Goods Sold | 83.16M | 90.65M | 96.9M | 158M | 5.05M | 6.34M | 6.06M | 0 | 0 | 483K |
COGS % of Revenue | 605.76% | 283.85% | 471.96% | 174.13% | 19.78% | 32.15% | 7.76% | - | - | - |
Gross Profit | -69.43M▲ 0% | -58.72M▲ 15.4% | -76.37M▼ 30.1% | -67.26M▲ 11.9% | 20.49M▲ 130.5% | 13.38M▼ 34.7% | 72.06M▲ 438.8% | 32.31M▼ 55.2% | 40.52M▲ 25.4% | 38.21M▲ 0% |
Gross Margin % | -505.76% | -183.85% | -371.96% | -74.13% | 80.22% | 67.85% | 92.24% | 100% | 100% | 98.75% |
Gross Profit Growth % | -36.34% | 15.43% | -30.06% | 11.92% | 130.46% | -34.73% | 438.76% | -55.16% | 25.39% | - |
Operating Expenses | 133.66M | 145.66M | 64.56M | 67.58M | 213.64M | 239.32M | 241.24M | 283.47M | 139.86M | 153.32M |
OpEx % of Revenue | 973.64% | 456.1% | 314.43% | 74.48% | 836.35% | 1214.11% | 308.8% | 877.22% | 345.15% | - |
Selling, General & Admin | 50.5M | 55.01M | 64.56M | 67.58M | 76.18M | 70.7M | 69.65M | 71.99M | 49.9M | 46.76M |
SG&A % of Revenue | 367.88% | 172.25% | 314.43% | 74.48% | 298.24% | 358.69% | 89.16% | 222.77% | 123.16% | - |
Research & Development | 83.16M | 90.65M | 96.9M | 158M | 142.51M | 174.96M | 177.65M | 199.25M | 89.95M | 66.19M |
R&D % of Revenue | 605.76% | 283.85% | 471.96% | 174.13% | 557.89% | 887.57% | 227.4% | 616.6% | 222% | - |
Other Operating Expenses | 587K | 328K | -96.9M | -158M | -5.05M | -6.34M | -6.06M | 12.23M | 0 | 2M |
Operating Income | -119.93M▲ 0% | -113.73M▲ 5.2% | -140.92M▼ 23.9% | -134.84M▲ 4.3% | -193.15M▼ 43.2% | -225.95M▼ 17.0% | -169.18M▲ 25.1% | -251.15M▼ 48.5% | -99.34M▲ 60.4% | -115.11M▲ 0% |
Operating Margin % | -873.64% | -356.1% | -686.39% | -148.61% | -756.13% | -1146.26% | -216.56% | -777.22% | -245.15% | -297.5% |
Operating Income Growth % | -23.4% | 5.17% | -23.91% | 4.32% | -43.24% | -16.98% | 25.12% | -48.45% | 60.45% | - |
EBITDA | -117.25M | -110.47M | -138.09M | -130.88M | -188.09M | -219.61M | -163.12M | -245.34M | -94.06M | -111.27M |
EBITDA Margin % | -854.09% | -345.91% | -672.6% | -144.25% | -736.35% | -1114.11% | -208.8% | -759.25% | -232.13% | -287.57% |
EBITDA Growth % | -22.15% | 5.78% | -25% | 5.22% | -43.71% | -16.76% | 25.73% | -50.41% | 61.66% | 56.2% |
D&A (Non-Cash Add-back) | 2.68M | 3.25M | 2.83M | 3.96M | 5.05M | 6.34M | 6.06M | 5.81M | 5.28M | 3.84M |
EBIT | -119.35M | -113.73M | -140.92M | -134.84M | -193.15M | -225.95M | -169.18M | -238.92M | -153.89M | -105.02M |
Net Interest Income | -978K | 3.44M | 7.31M | 2.6M | 607K | 5.52M | 17.57M | 14.06M | 2.14M | -366K |
Interest Income | 0 | 3.44M | 7.31M | 2.6M | 607K | 5.52M | 17.57M | 14.06M | 8.31M | -1.51M |
Interest Expense | 978K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6.17M | -1.14M |
Other Income/Expense | -391K | 3.77M | 7.18M | 18.86M | 644K | 5.52M | 15.96M | 14.06M | -60.72M | 6.16M |
Pretax Income | -120.32M▲ 0% | -109.95M▲ 8.6% | -133.75M▼ 21.6% | -115.98M▲ 13.3% | -192.5M▼ 66.0% | -220.43M▼ 14.5% | -153.22M▲ 30.5% | -237.09M▼ 54.7% | -160.06M▲ 32.5% | -108.95M▲ 0% |
Pretax Margin % | -876.49% | -344.28% | -651.43% | -127.82% | -753.61% | -1118.26% | -196.13% | -733.72% | -395.01% | -281.59% |
Income Tax | -1.12M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.93% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -120.32M▲ 0% | -109.95M▲ 8.6% | -133.75M▼ 21.6% | -115.98M▲ 13.3% | -192.5M▼ 66.0% | -220.43M▼ 14.5% | -153.22M▲ 30.5% | -237.09M▼ 54.7% | -160.06M▲ 32.5% | -108.95M▲ 0% |
Net Margin % | -876.49% | -344.28% | -651.43% | -127.82% | -753.61% | -1118.26% | -196.13% | -733.72% | -395.01% | -281.59% |
Net Income Growth % | -23.81% | 8.62% | -21.64% | 13.29% | -65.98% | -14.51% | 30.49% | -54.74% | 32.49% | 56.63% |
Net Income (Continuing) | -120.32M | -109.95M | -133.75M | -115.98M | -192.5M | -220.43M | -153.22M | -237.09M | -160.06M | -108.95M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -2.98▲ 0% | -2.33▲ 21.8% | -2.47▼ 6.0% | -1.98▲ 19.8% | -2.85▼ 43.9% | -3.21▼ 12.6% | -2.02▲ 37.1% | -2.88▼ 42.6% | -1.80▲ 37.5% | -1.11▲ 0% |
EPS Growth % | 1.32% | 21.81% | -6.01% | 19.84% | -43.94% | -12.63% | 37.07% | -42.57% | 37.5% | 59.61% |
EPS (Basic) | -2.98 | -2.33 | -2.47 | -1.98 | -2.85 | -3.21 | -2.02 | -2.88 | -1.80 | - |
Diluted Shares Outstanding | 40.32M | 47.1M | 49.98M | 58.61M | 67.62M | 68.66M | 75.97M | 82.34M | 88.75M | 97.88M |
Basic Shares Outstanding | 40.32M | 47.1M | 49.98M | 58.61M | 67.62M | 68.66M | 75.97M | 82.34M | 88.75M | 97.88M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
EDIT Balance Sheet
Editas Medicine, Inc. (EDIT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 332.2M | 374.78M | 463.84M | 419.09M | 507.31M | 356.75M | 340.83M | 289.31M | 163.9M | 128.07M |
Cash & Short-Term Investments | 329.14M | 368.95M | 457.14M | 402.11M | 499.85M | 344.27M | 323.11M | 269.91M | 146.65M | 123.65M |
Cash Only | 146.63M | 134.78M | 238.18M | 139.68M | 203.52M | 141.52M | 123.65M | 131.54M | 146.65M | 123.65M |
Short-Term Investments | 182.51M | 234.18M | 218.96M | 262.43M | 296.33M | 202.75M | 199.46M | 138.37M | 0 | 0 |
Accounts Receivable | 679K | 30K | 418K | 6.05M | 267K | 5.14M | 10.19M | 16.27M | 15.18M | 2.59M |
Days Sales Outstanding | 18.05 | 0.34 | 7.43 | 24.33 | 3.82 | 95.27 | 47.59 | 183.73 | 136.7 | 62.46 |
Inventory | 1.86M | 2.92M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | 8.18 | 11.75 | - | - | - | - | - | - | - | - |
Other Current Assets | 517K | 0 | 6.29M | 0 | 0 | 7.33M | 7.53M | 3.14M | 2.07M | 1.83M |
Total Non-Current Assets | 41.06M | 45.61M | 45.04M | 153.51M | 170.17M | 157.57M | 158.32M | 52.27M | 22.64M | 21.27M |
Property, Plant & Equipment | 39.44M | 40.23M | 39.65M | 39.15M | 43.29M | 59.22M | 45.71M | 47.05M | 19.66M | 18.3M |
Fixed Asset Turnover | 0.35x | 0.79x | 0.52x | 2.32x | 0.59x | 0.33x | 1.71x | 0.69x | 2.06x | 1.86x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 1.62M | 5.38M | 3.67M | 109.66M | 120.07M | 93.1M | 104.02M | 0 | 2.7M | 8.04M |
Other Non-Current Assets | 0 | 0 | 1.73M | 4.7M | 6.81M | 5.25M | 8.59M | 5.22M | 276K | 306K |
Total Assets | 373.26M▲ 0% | 420.39M▲ 12.6% | 508.88M▲ 21.1% | 572.6M▲ 12.5% | 677.48M▲ 18.3% | 514.32M▼ 24.1% | 499.15M▼ 2.9% | 341.59M▼ 31.6% | 186.53M▼ 45.4% | 149.34M▲ 0% |
Asset Turnover | 0.04x | 0.08x | 0.04x | 0.16x | 0.04x | 0.04x | 0.16x | 0.09x | 0.22x | 0.21x |
Asset Growth % | 62.87% | 12.63% | 21.05% | 12.52% | 18.32% | -24.08% | -2.95% | -31.57% | -45.39% | -172.43% |
Total Current Liabilities | 36.71M | 35.9M | 59.96M | 58.21M | 46.88M | 60.11M | 63.22M | 77.22M | 46.25M | 39.78M |
Accounts Payable | 4.02M | 5.33M | 5.84M | 6.41M | 5.05M | 9.51M | 8.27M | 5.49M | 2.6M | 4.33M |
Days Payables Outstanding | 17.64 | 21.45 | 22.01 | 14.8 | 364.78 | 547.82 | 497.72 | - | - | 3.18K |
Short-Term Debt | 7.5M | 0 | 0 | 0 | 0 | 0 | 12M | 0 | 11.03M | 14.2M |
Deferred Revenue (Current) | 13.24M | 15.71M | 23.51M | 20.94M | 11.33M | 8.22M | 8.22M | 11.22M | 44.51M | 103.71M |
Other Current Liabilities | 8.24M | 9.66M | 19.83M | 5.32M | 10.16M | 10.14M | -723K | 21.99M | -11.9M | 18.47M |
Current Ratio | 9.05x | 10.44x | 7.74x | 7.20x | 10.82x | 5.94x | 5.39x | 3.75x | 3.54x | 3.22x |
Quick Ratio | 9.00x | 10.36x | 7.74x | 7.20x | 10.82x | 5.94x | 5.39x | 3.75x | 3.54x | 3.22x |
Cash Conversion Cycle | 8.59 | -9.36 | - | - | - | - | - | - | - | -3.12K |
Total Non-Current Liabilities | 128.47M | 148.32M | 186.49M | 120.81M | 76.96M | 93.53M | 86.84M | 130.09M | 113M | 105.15M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53.6M | 47.18M |
Capital Lease Obligations | 33.43M | 32.42M | 23.28M | 19.32M | 16.07M | 32.86M | 24.37M | 20.38M | 12.07M | 51.22M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 317K | 293K | 1K | 27.5M | 0 | 0 | 1.8M | 3.07M | 2.81M | 2.87M |
Total Liabilities | 165.18M | 184.22M | 246.45M | 179.02M | 123.84M | 153.64M | 150.06M | 207.31M | 159.25M | 144.93M |
Total Debt | 33.43M | 32.42M | 29.08M | 26.14M | 26.38M | 43.95M | 48.54M | 35.03M | 76.71M | 71.97M |
Net Debt | -113.2M | -102.36M | -209.1M | -113.55M | -177.14M | -97.58M | -75.11M | -96.51M | -69.94M | -51.67M |
Debt / Equity | 0.16x | 0.14x | 0.11x | 0.07x | 0.05x | 0.12x | 0.14x | 0.26x | 2.81x | 16.33x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.65x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.46x |
Interest Coverage | -122.03x | - | - | - | - | - | - | - | -24.94x | 91.80x |
Total Equity | 208.08M▲ 0% | 236.16M▲ 13.5% | 262.44M▲ 11.1% | 393.59M▲ 50.0% | 553.64M▲ 40.7% | 360.68M▼ 34.9% | 349.1M▼ 3.2% | 134.27M▼ 61.5% | 27.29M▼ 79.7% | 4.41M▲ 0% |
Equity Growth % | 54.58% | 13.5% | 11.13% | 49.97% | 40.67% | -34.85% | -3.21% | -61.54% | -79.68% | -356.69% |
Book Value per Share | 5.16 | 5.01 | 5.25 | 6.72 | 8.19 | 5.25 | 4.60 | 1.63 | 0.31 | 0.05 |
Total Shareholders' Equity | 208.08M | 236.16M | 262.44M | 393.59M | 553.64M | 360.68M | 349.1M | 134.27M | 27.29M | 4.41M |
Common Stock | 4K | 5K | 5K | 6K | 7K | 7K | 8K | 8K | 10K | 10K |
Retained Earnings | -305.85M | -416.28M | -549.22M | -665.2M | -857.7M | -1.08B | -1.23B | -1.47B | -1.63B | -1.65B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -76K | -29K | 107K | -46K | -493K | -3.6M | 198K | 268K | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EDIT Cash Flow Statement
Editas Medicine, Inc. (EDIT) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -9.42M | -45.71M | -40.67M | -179.84M | -163.8M | -177.35M | -132.18M | -210.28M | -165.24M | -140.5M |
Operating CF Margin % | -68.6% | -143.12% | -198.09% | -198.21% | -641.26% | -899.7% | -169.19% | -650.75% | -407.8% | - |
Operating CF Growth % | 81.14% | -385.37% | 11.02% | -342.21% | 8.92% | -8.27% | 25.47% | -59.09% | 21.42% | 133.43% |
Net Income | -120.32M | -109.95M | -133.75M | -115.98M | -192.5M | -220.43M | -153.22M | -237.09M | -160.06M | -108.95M |
Depreciation & Amortization | 2.68M | 3.25M | 2.83M | 3.96M | 5.05M | 6.34M | 6.06M | 5.81M | 5.28M | 4.17M |
Stock-Based Compensation | 23.36M | 26.6M | 27.24M | 23.16M | 43.4M | 29.29M | 19.8M | 21.42M | 10M | 9.12M |
Deferred Taxes | 0 | -3.67M | 0 | -16.37M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 14.2M | 11.17M | -2.93M | 27.6M | 1.66M | -724K | -3.23M | -3.87M | 10.77M | 5.85M |
Working Capital Changes | 70.66M | 26.89M | 65.93M | -102.22M | -21.41M | 8.18M | -1.59M | 3.45M | -31.23M | -50.69M |
Change in Receivables | -591K | 649K | -388K | -5.63M | 5.78M | -4.88M | -5.04M | -6.08M | 1.09M | -2.08M |
Change in Inventory | -8.94M | 1.57M | 10.65M | -5.65M | -3.35M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -1.51M | 1.78M | 274K | 855K | -1.14M | 4.37M | -1.49M | -2.29M | -2.89M | -1.13M |
Cash from Investing | -183.81M | -53.09M | 12.25M | -140.52M | -54.47M | 114.07M | -3.73M | 162.15M | 138.67M | 82.34M |
Capital Expenditures | -2.06M | -4.75M | -6.17M | -7.16M | -7.98M | -4.12M | -4.72M | -8.83M | -607K | -434K |
CapEx % of Revenue | 15% | 14.89% | 30.04% | 7.89% | 31.23% | 20.89% | 6.04% | 27.31% | 1.5% | 1.12% |
Acquisitions | 15K | 37K | 102K | 12K | 46.49M | 18K | 0 | 0 | 269K | 274K |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 15K | 37K | 0 | 0 | -46.49M | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 154.53M | 86.94M | 131.82M | 224.12M | 282.11M | 1.28M | 118.04M | 56.03M | 40.47M | 41.91M |
Debt Issued (Net) | -764K | -857K | 0 | 0 | 0 | 0 | 0 | 0 | -2.87M | -2.87M |
Equity Issued (Net) | 0 | 76.79M | 116.34M | 203.73M | 249.46M | 1.28M | 117.08M | 56.03M | 43.34M | 41.89M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 228K |
Other Financing | 155.3M | 11.01M | 15.48M | 20.4M | 32.65M | 0 | 960K | 0 | 0 | 2.89M |
Net Change in Cash | -38.69M▲ 0% | -11.85M▲ 69.4% | 103.41M▲ 972.3% | -96.24M▼ 193.1% | 63.84M▲ 166.3% | -62M▼ 197.1% | -17.87M▲ 71.2% | 7.89M▲ 144.1% | 13.9M▲ 76.2% | -16.25M▲ 0% |
Free Cash Flow | -11.48M▲ 0% | -50.46M▼ 339.7% | -46.84M▲ 7.2% | -187M▼ 299.3% | -171.78M▲ 8.1% | -181.47M▼ 5.6% | -136.9M▲ 24.6% | -219.11M▼ 60.1% | -165.85M▲ 24.3% | -141.09M▲ 0% |
FCF Margin % | -83.6% | -158% | -228.12% | -206.11% | -672.49% | -920.59% | -175.23% | -678.07% | -409.3% | -364.63% |
FCF Growth % | 78.52% | -339.71% | 7.18% | -299.28% | 8.14% | -5.64% | 24.56% | -60.05% | 24.31% | 34.46% |
FCF per Share | -0.28 | -1.07 | -0.94 | -3.19 | -2.54 | -2.64 | -1.80 | -2.66 | -1.87 | -1.44 |
FCF Conversion (FCF/Net Income) | 0.08x | 0.42x | 0.30x | 1.55x | 0.85x | 0.80x | 0.86x | 0.89x | 1.03x | 1.29x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EDIT Key Ratios
Editas Medicine, Inc. (EDIT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -70.22% | -49.5% | -53.65% | -35.36% | -40.65% | -48.22% | -43.17% | -98.1% | -198.14% | -677.39% |
Return on Invested Capital (ROIC) | -226.97% | -74.6% | -112.96% | -60.67% | -44.13% | -52.99% | -47.25% | -120.84% | - | 107.69% |
Gross Margin | -505.76% | -183.85% | -371.96% | -74.13% | 80.22% | 67.85% | 92.24% | 100% | 100% | 98.75% |
Net Margin | -876.49% | -344.28% | -651.43% | -127.82% | -753.61% | -1118.26% | -196.13% | -733.72% | -395.01% | -281.59% |
Debt / Equity | 0.16x | 0.14x | 0.11x | 0.07x | 0.05x | 0.12x | 0.14x | 0.26x | 2.81x | 16.33x |
Interest Coverage | -122.03x | - | - | - | - | - | - | - | -24.94x | 91.80x |
FCF Conversion | 0.08x | 0.42x | 0.30x | 1.55x | 0.85x | 0.80x | 0.86x | 0.89x | 1.03x | 1.29x |
Revenue Growth | 126.8% | 132.64% | -35.71% | 341.93% | -71.85% | -22.83% | 296.32% | -58.64% | 25.39% | 7.97% |
Related:EDIT Dividend History·EDIT Revenue History·EDIT Price History·EDIT P/E History·EDIT Financial Ratios·EDIT Institutional Holders
EDIT SEC Filings & Documents
Editas Medicine, Inc. (EDIT) SEC filings — annual & quarterly reports (10-K, 10-Q)
EDIT Frequently Asked Questions
Editas Medicine, Inc. (EDIT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Editas Medicine, Inc. (EDIT) reported $38.7M in revenue for fiscal year 2025.
Editas Medicine, Inc. (EDIT) grew revenue by 25.4% over the past year. This is strong growth.
Editas Medicine, Inc. (EDIT) reported a net loss of $109.0M for fiscal year 2025.
Dividend & Returns
Editas Medicine, Inc. (EDIT) has a return on equity (ROE) of -198.1%. Negative ROE indicates the company is unprofitable.
Editas Medicine, Inc. (EDIT) had negative free cash flow of $141.1M in fiscal year 2025, likely due to heavy capital investments.